Literature DB >> 16259799

Development of a method for the measurement of dehydroepiandrosterone sulphate by liquid chromatography-tandem mass spectrometry.

C A Chadwick1, L J Owen, B G Keevil.   

Abstract

BACKGROUND: Dehydroepiandrosterone sulphate (DHEAS) is a steroid that is increasingly being recognized as a potential drug of abuse in many countries. This is due to its reputation as a hormone that may be able to retard the ageing process. The measurement of DHEAS is useful in the diagnosis of medical conditions such as congenital adrenal hyperplasia and polycystic ovary syndrome. Thus, a liquid chromatography-tandem mass spectrometry method has been developed to determine DHEAS concentrations in human serum.
METHOD: The chromatography was performed using a Waters 2795 Alliance HT LC system coupled to a Mercury Fusion-RP column fitted with a SecurityGuard column.
RESULTS: DHEAS and the internal standard, deuterated DHEAS, both had a retention time of 1.5 min. The transition determined by the Micromass Quattro tandem mass spectrometer for DHEAS was m/z 367.3>4 96.7 and for the internal standard m/z 369.3>96.6. The method was linear up to 20 micromol/L; the lower limit of detection and the lower limit of quantitation were both 1 micromol/L. The intra- and interassay imprecision were <11% over a concentration range of 1-18 micromol/L for the in-house quality control and <12% for the intra- and interassay imprecision for the Bio-Rad Lyphocheck QC.
CONCLUSION: The measurement of DHEAS by liquid chromatography-tandem mass spectrometry is robust and has a simple sample preparation procedure with a rapid cycle time of only 4 min.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16259799     DOI: 10.1258/000456305774538175

Source DB:  PubMed          Journal:  Ann Clin Biochem        ISSN: 0004-5632            Impact factor:   2.057


  11 in total

1.  Alterations in Gut Microbiome Composition and Barrier Function Are Associated with Reproductive and Metabolic Defects in Women with Polycystic Ovary Syndrome (PCOS): A Pilot Study.

Authors:  Lisa Lindheim; Mina Bashir; Julia Münzker; Christian Trummer; Verena Zachhuber; Bettina Leber; Angela Horvath; Thomas R Pieber; Gregor Gorkiewicz; Vanessa Stadlbauer; Barbara Obermayer-Pietsch
Journal:  PLoS One       Date:  2017-01-03       Impact factor: 3.240

2.  AKR1C3-Mediated Adipose Androgen Generation Drives Lipotoxicity in Women With Polycystic Ovary Syndrome.

Authors:  Michael W O'Reilly; Punith Kempegowda; Mark Walsh; Angela E Taylor; Konstantinos N Manolopoulos; J William Allwood; Robert K Semple; Daniel Hebenstreit; Warwick B Dunn; Jeremy W Tomlinson; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2017-09-01       Impact factor: 5.958

3.  Androsterone glucuronide to dehydroepiandrosterone sulphate ratio is discriminatory for obese Caucasian women with polycystic ovary syndrome.

Authors:  Li-Wei Cho; Thozhukat Sathyapalan; Eric S Kilpatrick; Brian G Keevil; Adrian G Miller; Anne M Coady; Lina Ahmed; Stephen L Atkin
Journal:  BMC Endocr Disord       Date:  2017-05-19       Impact factor: 2.763

4.  11-Oxygenated C19 Steroids Are the Predominant Androgens in Polycystic Ovary Syndrome.

Authors:  Michael W O'Reilly; Punith Kempegowda; Carl Jenkinson; Angela E Taylor; Jonathan L Quanson; Karl-Heinz Storbeck; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2017-03-01       Impact factor: 5.958

5.  Mapping the Steroid Response to Major Trauma From Injury to Recovery: A Prospective Cohort Study.

Authors:  Mark A Foster; Angela E Taylor; Neil E Hill; Conor Bentley; Jon Bishop; Lorna C Gilligan; Fozia Shaheen; Julian F Bion; Joanne L Fallowfield; David R Woods; Irina Bancos; Mark M Midwinter; Janet M Lord; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2020-03-01       Impact factor: 5.958

6.  Comparison of the efficacy of different androgens measured by LC-MS/MS in representing hyperandrogenemia and an evaluation of adrenal-origin androgens with a dexamethasone suppression test in patients with PCOS.

Authors:  Fu Chen; Minjie Chen; Weichun Zhang; Huihuang Yin; Guishan Chen; Qingxia Huang; Xiaoping Yang; Lan Chen; Chujia Lin; Guoshu Yin
Journal:  J Ovarian Res       Date:  2021-02-14       Impact factor: 4.234

7.  Hyperandrogenemia predicts metabolic phenotype in polycystic ovary syndrome: the utility of serum androstenedione.

Authors:  Michael W O'Reilly; Angela E Taylor; Nicola J Crabtree; Beverly A Hughes; Farfia Capper; Rachel K Crowley; Paul M Stewart; Jeremy W Tomlinson; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2014-01-01       Impact factor: 5.958

8.  Steroid Sulfatase Deficiency and Androgen Activation Before and After Puberty.

Authors:  Jan Idkowiak; Angela E Taylor; Sandra Subtil; Donna M O'Neil; Raymon Vijzelaar; Renuka P Dias; Rakesh Amin; Timothy G Barrett; Cedric H L Shackleton; Jeremy M W Kirk; Celia Moss; Wiebke Arlt
Journal:  J Clin Endocrinol Metab       Date:  2016-03-22       Impact factor: 5.958

9.  The Salivary Microbiome in Polycystic Ovary Syndrome (PCOS) and Its Association with Disease-Related Parameters: A Pilot Study.

Authors:  Lisa Lindheim; Mina Bashir; Julia Münzker; Christian Trummer; Verena Zachhuber; Thomas R Pieber; Gregor Gorkiewicz; Barbara Obermayer-Pietsch
Journal:  Front Microbiol       Date:  2016-08-25       Impact factor: 5.640

10.  Primary adrenal insufficiency is associated with impaired natural killer cell function: a potential link to increased mortality.

Authors:  Irina Bancos; Jon Hazeldine; Vasileios Chortis; Peter Hampson; Angela E Taylor; Janet M Lord; Wiebke Arlt
Journal:  Eur J Endocrinol       Date:  2017-04       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.